Group B Streptococcus Awareness Month: Vaccine and Challenges Underway
Group B Streptococcus (GBS) is a leading cause of maternal, fetal and neonatal morbidity and mortality worldwide, being associated with 3.5 million preterm births, 319,000 neonatal infections and 147,000 neonatal deaths annually (Seale et al., 2017; Steer et al., 2020). Asymptomatic anovaginal colonization of pregnant women is the main risk factor for neonatal GBS infections, which are usually derived from vertical transmission. An estimated 18% of pregnant women worldwide are asymptomatically colonized by GBS (Seale et al., 2017), but this rate varies from 10 to 40% according to the country.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tatiana Castro Abreu Pinto, Laura Maria Andrade Oliveira, Nat ália Silva da Costa, Amanda de Assis Rocha, André Rio Tinto de Matos Freire, Carollina Moreira Franquelino Gutierrez, Crislaine Mateus dos Santos, Danielle Cristina dos Santos Silva Alvim, Dà Tags: Editorial Source Type: research
More News: Group B Streptococcus | Infectious Diseases | Perinatology & Neonatology | Pregnancy | Vaccines | Women